Sinthia Kabarah
Research Mentor(s): Jeffrey Montgomery
Mentor Department: Urology
Authors: Sinthia Kabarah, Sadia Islam, Julia Arnold, Jeffery Montgomery
Session: Session 5 (2:00pm – 2:50pm)
Presentation Type: Poster 64
Abstract
Neoadjuvant chemotherapy (NAC) could be an efficient solution to helping treat patients who are diagnosed with muscle-invasive bladder cancer. The goal of this project is to find out what is contributing to this underused solution. The data in this project was collected through an IRB-approved Bladder Cancer Database at Michigan Medicine. Our methodology is using the IRB-approved Bladder Cancer Database at Michigan Medicine which allows us to survey patients’ cystectomy treatments prior to and post-procedure. The surveys allow us to use patient’s demographic information through their approved consent. We also analyze the cystectomy recommendations and whether or not the patients went through with the cystectomy and take other medical factors into consideration. The data consists of patients’ pre-, during, and post-cystectomy data, and their demographic information. We also look at the T, N, and M stages of the patients in our database before and after their cystectomy if they have had one to see the improvements and changes that have happened post-cystectomy. This allows us to view the patterns in bladder cancer cystectomy outcomes including information on whether or not a patient received NAC and the reasons that could have impacted this choice. This comes from an analysis of the patient’s cystectomy status and neoadjuvant chemotherapy status, including whether they received the treatment or not and the elaborate reasoning behind that answer. Those with characteristics like poor renal function can make cystectomy treatments closer to trying to have a more successful NAC treatment. Although this is still an ongoing project, our findings in this project can lead to increased use of neoadjuvant chemotherapy and better patient care outcomes.
